Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

Publication date: January 2021Source: The Lancet Diabetes & Endocrinology, Volume 9, Issue 1Author(s): David C Wheeler, Bergur V Stefánsson, Niels Jongs, Glenn M Chertow, Tom Greene, Fan Fan Hou, John J V McMurray, Ricardo Correa-Rotter, Peter Rossing, Robert D Toto, C David Sjöström, Anna Maria Langkilde, Hiddo J L Heerspink, DAPA-CKD Trial Committees and Investigators
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research